InVivoSIM anti-human SLAMF7 (Elotuzumab Biosimilar)
Catalog #SIM0041
Clone:
Elotuzumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Elotuzumab, making it ideal for research use. Elotuzumab is a humanized monoclonal antibody that reacts with the cell surface glycoprotein CD319, which is commonly known as signaling lymphocytic activation molecule family member 7 (SLAMF7). SLAMF7 is highly expressed on myeloma cells, and in normal tissues, its expression is reported in natural killer (NK) cells, plasma cells, spleen cells, lymph nodes, peripheral blood leukocytes, bone marrow cells, etc. SLAMF7 is suggested to interact with SH2D1A, SH2D1B, PTPN6/SHP-1, PTPN11/SHP-2, INPP5D/SHIP1, CSK, and FYN proteins. Functionally, SLAMF7 is a self-ligand receptor of the SLAM family, and it is involved in the regulation and interconnection of both innate and adaptive immunity. Elotuzumab directly activates NK cells through both the SLAMF7 pathway and Fc receptor signaling. Elotuzumab also increases the expression of CD69 (on NK cells) and enhances IFN Ī³ secretion and granzyme B biosynthesis, independent of Fc receptor signaling. In myeloma cells, based on in vitro studies, Elotuzumab is reported to target SLAMF7 and facilitate the interaction with NK cells for promoting myeloma cell death through the antibody-dependent cellular cytotoxicity (ADCC) mechanism. Elotuzumab disrupts the cell adhesion-mediated mechanisms of drug resistance in multiple myeloma cells by inhibiting their binding to bone marrow stromal cells in vitro. Elotuzumab is shown to reduce the growth of SLAMF7+ human multiple myeloma OPM2 xenografts in mice. Experiments involving in vitro as well as in vivo preclinical models demonstrated that a combination of Elotuzumab with the thalidomide derivative lenalidomide leads to enhanced activation of NK cells and increased anti-tumor activity.Specifications
| Isotype | Human IgG1, Īŗ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | E356D/M358L |
| Immunogen | Human SLAMF7 |
| Reported Applications |
in vivo functional assays in vitro functional assays ELISA Western blot Immunoprecipitation Flow cytometry |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
<0.5EU/mg (<0.0005EU/Ī¼g) Determined by LAL gel clotting assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
>95% Determined by SDS-PAGE |
| Sterility | 0.2 Āµm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theilerās Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |
Recommended Products
-
Recommended Isotype Control(s)
RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer